Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis

Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer’s disease

(2015) Erik Portelius et al.   BRAIN

Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis

(2015) J. Kuhle et al.   NEUROLOGY

Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease

(2015) Maartje I. Kester et al.   JAMA Neurology

CSF levels of YKL-40 are increased in MS and decrease with immunosuppressive treatment

(2014) Clas Malmeström et al.   JOURNAL OF NEUROIMMUNOLOGY

Cell-selective knockout and 3D confocal image analysis reveals separate roles for astrocyte-and endothelial-derived CCL2 in neuroinflammation

(2014) Debayon Paul et al.   Journal of Neuroinflammation

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

(2014) Peter A Calabresi et al.   LANCET NEUROLOGY

Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis

(2013) Markus Axelsson et al.   Multiple Sclerosis Journal

Relationship between Cerebrospinal Fluid Biomarkers for Inflammation, Demyelination and Neurodegeneration in Acute Optic Neuritis

(2013) Signe Modvig et al.   PLoS One

Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing–Remitting Multiple Sclerosis (TRANSFORMS)

(2013) B.O. Khatri et al.   Multiple Sclerosis and Related Disorders

Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study

(2012) Virginia Devonshire et al.   LANCET NEUROLOGY

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

(2011) Chris H. Polman et al.   ANNALS OF NEUROLOGY

Fingolimod (FTY720) Enhances Remyelination Following Demyelination of Organotypic Cerebellar Slices

(2010) Veronique E. Miron et al.   AMERICAN JOURNAL OF PATHOLOGY

Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab

(2010) Martin Gunnarsson et al.   ANNALS OF NEUROLOGY

Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis

(2010) Manuel Comabella et al.   BRAIN

Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease

(2010) Annika Thorsell et al.   BRAIN RESEARCH

The role of monocyte chemoattractant protein MCP1/CCL2 in neuroinflammatory diseases

(2010) Grégory Conductier et al.   JOURNAL OF NEUROIMMUNOLOGY

Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis

(2010) M. Axelsson et al.   JOURNAL OF NEUROLOGY

Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course

(2010) Mohsen Khademi et al.   Multiple Sclerosis Journal

Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis

(2010) M. Mehling et al.   NEUROLOGY

Increased cerebrospinal fluid chitotriosidase index in patients with multiple sclerosis

(2009) M. M. Verbeek et al.   ACTA NEUROLOGICA SCANDINAVICA

Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS

(2009) F. Sellebjerg et al.   NEUROLOGY

A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking

(2009) C. E. Teunissen et al.   NEUROLOGY